Business

The Future of Pharmacy: Trends, Threats, Transformations

February 11th 2025

By Cameron Santoro

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

February 10th 2025

By Dracey Poore

Article

2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.

The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars

February 5th 2025

By Skylar Jeremias

Article

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.

The Banking of Biosimilars: Insights From a Leading Health Economist

February 4th 2025

By Skylar Jeremias

Article

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.

Welcome Wezlana: The First Stelara Biosimilar to Launch in the US

January 31st 2025

By Skylar Jeremias

Article

January 1 marks the launch of the first biosimilar referencing Stelara (ustekinumab) in the US, ushering in a new class of lower-cost medicines for patients with rheumatic and gastrointestinal conditions.

Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets

January 26th 2025

By Skylar Jeremias

Article

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements regarding new biosimilar products in Europe and Canada.

Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals

January 11th 2025

By Skylar Jeremias

Article

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.

Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration

December 10th 2024

By Skylar Jeremias

Article

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.

Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts

December 4th 2024

By Skylar Jeremias

Article

Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.

The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars

November 25th 2024

By Skylar Jeremias

Article

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.